Related Experiment Video
Updated: Jan 26, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.1K
[Juvenile idiopathic arthritis].
Florence A Aeschlimann1, Pierre Quartier1
1Rhumatologie pédiatrique, hôpital Necker- Enfants malades, Paris, France.
La Revue Du Praticien
|April 16, 2019
Summary
Juvenile idiopathic arthritis (JIA) is a common childhood rheumatic disease. Early, aggressive treatment with biologic agents improves outcomes, but lifelong monitoring is crucial.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Internal Medicine
Background:
- Juvenile idiopathic arthritis (JIA) is the most prevalent chronic inflammatory rheumatic condition in childhood.
- JIA presents as a diverse group of disorders marked by joint inflammation and potential extraarticular manifestations like uveitis.
- Prognosis and management strategies for JIA are contingent upon the specific subtype of the disease.
Purpose of the Study:
- To summarize the current understanding of Juvenile idiopathic arthritis (JIA).
- To highlight recent therapeutic advancements in managing JIA.
- To emphasize the importance of ongoing monitoring for JIA patients.
Main Methods:
- Review of current literature on Juvenile idiopathic arthritis.
- Analysis of recent treatment advances, including biologic agents.
- Discussion of disease course, management, and prognosis across JIA categories.
Main Results:
- Biologic agents have substantially decreased JIA-associated morbidity.
- Early and aggressive therapeutic interventions are key to delaying disease progression.
- A significant proportion of JIA cases may persist into adulthood.
Conclusions:
- Current JIA treatment focuses on early, aggressive strategies to improve patient outcomes.
- Despite advances, JIA often requires long-term management and careful monitoring.
- Understanding JIA heterogeneity is vital for tailoring treatment and predicting prognosis.
